Introduction
An important factor in evaluating the cost-benefit ratio of gene therapy in cystic fibrosis patients will be the participants' subjective experience of both the therapy and its long-term impact on well-being. A review of the few studies of quality of life in patients with airways disease cautions that it cannot be assumed that improvement in lung functioning will herald an improvement in subjective health. 1 Because gene therapy is so new little information is available on attitudes to this mode of treatment.
We have described elsewhere pre-clinical studies towards, 2 and clinical laboratory results of, 3 a phase I safety study of a single application of gene therapy in the form of DNA-liposomes to the nose of CF patients. The trial was double-blind, placebo-controlled with a 2-week run-in period for observation and pre-administration tests and a 4-week post-administration period for evaluation. This trial has provided a vehicle to carry out a pilot study on the attitudes, expectations, knowledge and quality of life of participants. The aim of the study was to develop a methodology by which these factors could be measured. We also wished to monitor the psychological functioning of the participants as psychological status, particularly depressive symptoms, is known to mediate subjective evaluation of health. 
Results

Patient recruitment
Of the 23 patients recruited to the phase I safety trial, 20 participated in the semi-structured interview at baseline. Of these 20, three were subsequently excluded from the main study due to illness and one because sufficient patients had been recruited to meet the target number. 16 Findings are reported on the 16 trial participants with a brief commentary on the four excluded patients.
Six of the 16 patients were male with a median age of 29 years (range 16 to 42). At baseline mean (s.d.) forced expiratory volume in 1 s (FEV 1 ) was 52.3 (22.9)% predicted. Mean (s.d.) Northern score was 6.13 (2.16).
Quantitative findings
The means and standard deviations of the SF-36 at week 3 are presented in Table 1 . Scores have been compared with those of a large British community sample 5 for which the confidence intervals for the difference between means are shown. Not surprisingly, subjective physical functioning, limitations on physical role and general health fell below that of the well reference group. There is no reported difference between the CF group and the community sample in social functioning, mental health and emotional role limitations. This is in accordance with the good psychosocial functioning of cystic fibrosis patients described in many previous studies. 6, 7 The week 16 scores, not reported here, as expected showed no significant change from the baseline scores.
Scores on the Family Assessment Device (mean 19.2, s.d. 5.2) indicate that the CF group came from families as well-adjusted as those in a large Canadian community 8 Only one patient had a score in the dysfunctional range.
On the Hospital Anxiety and Depression scale four of 16 CF patients reached criteria for 'caseness' on the anxiety scale. Community surveys indicate rates of around 7%, 9 rising to 12% in people with a current medical condition. 4 Thus our sample appears to have a relatively high proportion of anxious patients. The personal histories of the four most anxious patients would suggest that anxiety was a long-standing trait rather than a state induced by participation in the safety trial. At 16 weeks, rates of anxiety (4/16) were unchanged. No relationship was found between anxiety and either objective health status measures (% predicted FEV 1 and the Northern score) or subjective health (the SF-36). By contrast rates of depression were uncommonly low. No subjects reached criteria for caseness at 3 weeks and only one at week 16. There was however a significant correlation between low mood and subjective health status (r = 0.81, n = 14, P Ͻ 0.001) but no relationship between depression and objective health status. On the CF-12 the scores (mean 20, s.d. 2.3) stand as reference data for future comparisons with other CF groups.
Qualitative interviews
During the process of selecting the 16 patients to go into the study, 20 initial interviews were undertaken. Three patients were excluded because of illness during the runin period and one was excluded from the final cohort because sufficient patients had been recruited to meet the target number. All but one agreed to having the interview audiotaped. On average interviews lasted about 20-25 min.
Week 1 interview
Knowledge of cystic fibrosis and gene therapy: The first section of the interview covered different aspects of gene therapy knowledge. Nine of the 20 had originally learned about gene therapy from television or newspaper or magazine articles, six from the CF Trust Newsletter and five from clinical staff they had seen at visits to the hospital. In response to the question 'what do you know of gene therapy?' 10 patients claimed to have no knowledge of the rationale for gene therapy. The interviewer judged seven respondents to have demonstrated a little knowledge and two to be well informed. Sixteen stated that they had enough knowledge, only three saying they would like to know a little more. Importantly they felt able to ask for more information.
Expectations of gene therapy: On the optimism measure 'How likely do you think it is that gene therapy will be an effective treatment for cystic fibrosis one day?' on the 10 point scale from 0 (ineffective) to 10 (very effective) five patients declined to estimate. Scores ranged from 6 to 10 (mean 8.4; 95% CI 7.3 to 9.0). This positive endorsement was an emotional one as 14 modelled their views on 'gut feeling', only one basing the prediction on knowledge. Several predicted that babies and young children were most likely to benefit before any permanent lung damage occurred.
In response to the prompt 'What does your family think about gene therapy?' 15 of the interviewees had discussed gene therapy with their families and found family and friends very keen and supportive of gene therapy. Family and friends were often seen as the driving force behind patients taking part in experimental procedures; their enthusiasm fuelled by high hopes for a successful cure that was not necessarily shared by the patients.
Personal benefits: Patients were asked next whether they expected to benefit personally from gene therapy. Nine patients were either hopeful or very hopeful. Six had little or no hope of personal benefit. The rest were noncommittal. When asked 'In what way do you expect to benefit from gene therapy?' three patients thought they would not require any more intravenous antibiotics and another three thought they would get fewer chest infections. Two expected the treatment to slow down the deterioration in their health. One thought that it would result in him spending less time in hospital and another that it would bring about a cure in 10 years. The remainder were unable to speculate on how their quality of life might improve.
Fears and concerns: When asked 'What kind of niggles and concerns do you have about gene therapy?' 14 patients claimed to have no worries about potential risks from gene therapy. Two were concerned that it might make them worse; that they might get more infection, carcinoma or in some unspecified way upset the status quo. Another patient said he preferred not to think too deeply lest his worries increased. Three were noncommittal. There was a general assumption that doctors would not put them at risk. The main concern was catching infections from ward patients or equipment and concern about the potential amount of time hospital visits would entail. The three patients with the highest level of concern about gene therapy all reached clinical criteria for anxiety disorder on the HADS scale. Two of these felt gene therapy was unlikely to be of benefit to CF sufferers. Fears were that gene therapy was interfering with nature, that it could lead to an increase in infection, that adenoviral vectors (not being used here) were particularly dangerous, that undesirable mutations to other genetic material could accidentally occur.
Heart and lung transplants versus gene therapy: When patients were asked which of the two they thought might be the better treatment, 16 patients said they would prefer gene therapy to heart-lung transplantation and noone opted for transplant surgery. Most patients viewed gene therapy as easier than having a big operation; 'less hassle', avoiding having to face the emotional issue of donor organs and the physical stress of organ rejection. Most patients had witnessed the strain of waiting for transplants on other patients and families and did not want that for themselves. Some had seen patients die whilst waiting and did not view the operation as giving long-term success. On patient said 6-7 years extra life would not be enough for her to have the operation.
The nasal trial: Patients had been asked if they were interested in entering the nasal trial anything from 1 to 6 months before doing so. Fifteen patients said that they had received enough information about the project. Thirteen stated that they had no concerns or worries about taking part in the research project. One patient feared that he might get infection from wards and another that it did not sound very pleasant. Two including our most anxious patient had felt obliged to take part because volunteers were needed.
Most patients had a realistic understanding that no personal clinical benefit could be expected from participation in the safety trial. Four patients hoped that taking part would accelerate their chance of being amongst the first to get the 'real thing' and four hoped to gain some clinical benefit, but for most altruism was the motivating factor.
Week 6 qualitative interviews
Patients were re-interviewed at 6 weeks both to relate their experience of the treatment process and to establish whether attitudes and expectations to gene therapy had changed.
Participation in nasal study: Seven patients stated that participating in the trial had been no problem, if a little tiring. Three had found it very tedious and felt tired from travelling and two patients experienced the process as traumatic, painful and uncomfortable. In the week in which daily visits to the clinic took place half found the visits long and time-consuming. Asked if any part of the study was unpleasant, nine patients found either the nasal brushings, biopsies or daily PDs unpleasant and tedious. The position patients were asked to hold during nasal PDs were uncomfortable for the back and shoulders with elbows leaning on the table. Most had experienced no side-effects after therapy. Two had pain after the nasal biopsies. One of the anxious patients had a panic attack during the procedure.
Twelve patients felt that they had not been affected in any way by the trial schedule and almost all thought that they had placed themselves at no risk whatsoever by taking part in the safety trial. The number of patients worried about taking part in a gene therapy trial was unchanged by the experience of being in the trial.
Hopes and expectations:
Patients were asked again 'How likely do you think it is that gene therapy will be an effective treatment for CF one day?' High optimism remained with the mean score of 8 on the 10-point scale, unchanged from baseline. They were asked again if in the future they expected to benefit personally from gene therapy. Five patients predicted suffering fewer chest infections and therefore having less i.v. antibiotics and five that their condition would stabilise. Three hoped the condition of their lungs would improve, that they would have more energy and perhaps gain weight. One worried that attending the ward might put him at extra risk of catching infections and another had thought if something went wrong perhaps lung damage might be accelerated rather than slowed down by gene therapy. Thus expectations of benefit had been slightly raised by receiving gene therapy but patients were mainly still realistic about personal benefit.
Interviews weeks 16-18
Interviews were undertaken at this later stage when all the nasal trial visits were over to find out how patients now viewed their own health and whether time had altered their opinion of gene therapy. Eighteen interviews were obtained from the original 20 patients who gave interviews at the start of the trial. The three patients who were excluded from the therapy trial during the run-in period will be dealt with separately at the end of this section.
Half the sample felt that their health in the 4 months since entering the trial was unchanged. None attributed health improvement or deterioration to participation in the study. All the patients were willing to help further research work and did not feel overburdened by requests.
Most patients were happy with how things were handled for them. Three recalled the nasal PDs as a particularly uncomfortable experience. Most patients had not discussed the outcome of the trial with their doctors at the CF clinic.
Asked if their attitudes to gene therapy had changed during the course of the trial, most felt their views had not changed, although five were now more enthusiastic. Enthusiasm remained high with a mean score of 8 (range 6-10) on the optimism scale.
Patients excluded from gene therapy nasal trial: Three of the four patients excluded from the trial after baseline assessment were interviewed at week 16 to assess whether rejection from the trial might influence attitudes to gene therapy. All were disappointed at not being entered into the trial but none were put off wanting to get involved again. With only three patients to be interviewed any conclusion must be tentative yet the responses of these few patients seemed little different from the trial completers. They were marginally (mean 7) less enthusiastic (optimism measure) about the potential of gene therapy as a form of treatment for CF than the main group.
Discussion
Most participants in the safety trial had no significant concerns and worries and described an emotionally driven optimism about the future of gene therapy. Participants reported that family and friends were often the driving force behind the decision to take part in novel procedures and were more optimistic about gene therapy than the patients. Patients' expectations about benefits to themselves from the safety trial itself were realistic. Patients remained optimistic about gene therapy after the trial and this optimism had not faded in subsequent weeks.
A small subgroup of patients with anxiety disorders had concerns about the safety, efficacy and unpleasant invasiveness of gene therapy. Rather than screen such patients out of trials (which might serve to raise anxiety levels) sensitivity to their emotional needs during the treatment process might be indicated.
Patients were mainly content with the information they had about gene therapy although most claimed to have little knowledge and understanding of the procedure. Considerable efforts had in fact been made to inform patients. As part of the process of recruiting patients and obtaining informed consent there were several consultations with the research clinician and an information sheet about gene therapy and the nasal trial. However we did not formally assess patients' knowledge.
To our knowledge this is the first psychological study of participants in a gene therapy trial. Both the physical and psychological health status of this sample would suggest that the participants were representative of the adult population of cystic fibrosis clinics in the UK. Robust conclusions are obviously premature due to the small sample size.
Because gene therapy is so new, little information is as yet available on public attitudes to this mode of treatment. A 1991 general public survey found that 71% of respondents were comfortable with the idea of genetic manipulation to cure disease 10 although only a modest 47% in a separate survey thought prenatal screening with a view to termination should be available for cystic fibrosis.
11 Population-based screening for cystic fibrosis seems to have little influence on reproductive intentions or behaviour. 12 It may be that gene therapy is seen as preferable to selective termination by the public.
Our respondents had positive attitudes to gene therapy and showed a clear preference for this approach over heart-lung transplantation. The immense psychological problems of patients and their families drawn into the transplantation programme has been commented on elsewhere. 13 Patients did not voice concerns about the stuff of science fiction: crazed scientists, eugenic abuse, the creation of chimeras, their concerns being over more prosaic issues such as the risk of infection from the ward and from equipment and disruption to their lives.
An objective of this pilot study was to develop a methodology whereby attitudes and quality of life measurements could be assessed in gene therapy trials for cystic fibrosis. The qualitative approach to gathering the main attitudinal data from patients has produced sufficient material to enable us to frame some patient-driven questions for use with survey methodology which is cheaper to execute and easier to analyse. Patients with anxiety disorders (4/16) had attitudes that deviated considerably from the group and underlined the need to assess mental health status. The brief HAD measure seemed satisfactory for the task. The SF-36 and CF-12 had face validity but we will not know if they are sensitive measures of change in subjective health status until treatment trials are conducted. The FAM scale added little useful information and could safely be abandoned.
In conclusion, we consider that there is a place for, and continuing value in, quantitative psychosocial studies in parallel with clinical studies of gene therapy. This study has highlighted the relevance of anxiety measures in assessing the suitability of patients for enrolment into such studies at this early stage in their development. It will be useful to monitor how knowledge of gene therapy and the request for information changes as this research becomes more widely assimilated into public knowledge and, in particular, is disseminated through the CF community. The mode of administration and the method of investigation (nasal PD, biopsy and brushing) had a direct bearing upon the attitudes of participants. It will be of interest to determine how this changes and what new issues, if any, arise with progression to lung studies and attendant changes in clinical and investigative procedures.
Patients and methods
Written informed consent was obtained from the adult patient volunteers recruited from cystic fibrosis clinics in Edinburgh and Glasgow who were participating in the safety trial. A semi-structured qualitative interview was carried out by a research nurse (EK) as part of the week 1 baseline assessment and audiotaped for later analysis. On average interviews lasted 20-25 min. At week 3, patients completed three self-report questionnaires: the Family Assessment Device, the Hospital Anxiety and Depression scale and the SF-36 scale. Shorter interviews took place at week 6 and at the week 16 follow-up. At week 16 the CF-12 Quality of Life measure was given and repeat measures of the HAD and SF-36.
Measures
(1) The SF-36 14 is a brief measure of subjective health status covering eight domains of health both physical and emotional. We used the UK developmental version of the scale. For each dimension item scores are coded, scored and transformed on a scale from 0 (worst health) to 100 (best health).
(2) The Hospital Anxiety and Depression Scale (HAD) 15 is a 14-item self-report scale that detects depression and anxiety in a medical outpatient setting. A cut-off score of 10 or more was used to define caseness. (3) Family functioning was measured with the 12-item general functioning scale of the Family Assessment Device. 16 It can be scored either as a continuous scale ranging from 12 to 48 or as a categorical measure with a score of 27 or greater defined as 'dysfunctional'. (4) In addition to the SF-36, a more disease-specific sub-jective health measure (the CF-12) relevant to cystic fibrosis patients was developed for use on this project (see Appendix 1) . Patients were asked to endorse for the previous week, 12 items (eg 'Have you had trouble bringing up sputum?') This approach was based on the approach of the EORTC Q-30 quality of life scales under development with cancer patients. 17 (5) Optimism measure. Participants were asked to rate the question 'How likely do you think it is that gene therapy will be an effective treatment for CF one day?' on a scale from 0 (ineffective) to 10 (effective).
